Digestive Oncology Studies

A phase 3, randomized trial with trastuzumab-deruxtecan (T-dxd) and Rilvegostomig versus standard gemcitabine, cisplatin, and durvalumab for primary care locally advanced or metastatic HER2 expression of biliary tract cancer.

Een fase 1b/2, multicenter, gerandomiseerde, open-label studie om de werkzaamheid en veiligheid van GSK5764227 alleen en in combinatie te evalueren bij deelnemers met eerder behandelde gevorderde niet-reseceerbare of gemetastaseerde colorectale tumoren.

‍

A phase 2, open-label, randomized trial of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in patients with previously untreated T4N0 or stage III MMRP/MSS colon cancer.

Het mogelijk maken van de-escalatie van adjuvante behandeling doormiddel van MRD-klaring bij vloeibare biopsies - het begeleiden van duidelijkebehandelbeslissingen in de curatieve setting van stadium II of III colonkanker.

A multicenter, open-label, randomized, controlled phase II trial comparing the efficacy of RO7198457 versus watchful waiting in patients with resected colorectal cancer into stage II (high risk) and stage III who ctDNA positive are after resection.

A phase 3, randomized, open-label, actively controlled trial of Sotorasib, Panitumumab and Folfiri versus researcher choice (Folfox or Folfiri) with or without Bevacizumab for the treatment of naive metastatic colorectal cancer patients with KRAS P.G12c mutation.

One open-label, randomized trial where one investigates the usefulness of the continuation of somatostatin analogs after progression in patients with neuroendocrine tumors (NET) of the stomach, intestine, or pancreas who not hormonally active is.

Research project around the search for biomarkers for treatment with immunotherapy in Hepatocellular Carcinoma (HCC).

Stereotactic radiation for the treatment of patients with a inoperable, non-metastatic pancreatic tumour: one randomized phase II trial.

Preoperative treatment with mFolfirinox (or Gem-Nab-P) +/- isotoxic high-dose stereotactic body radiation therapy (IHD-SBRT) for borderline resectable pancreatic adenocarcinoma: a randomized phase II trial.

A phase 3, randomized, double-blind trial, where the muscle mass is measured from patients with colon cancer or lung cancer who, during treatment, a oral food supplement with high protein and energy content drink. The research will determine whether the new dietary supplement can limit muscle breakdown during treatment.